10 growth stocks in the S&P 500's bargain -2-
Let's sort the S&P 500 healthcare sector again to show the 10 stocks with the highest percentages of "buy" or equivalent ratings. Only five companies are on both this list and the above growth list: ...
drugdeliverybusiness16h
Are over-the-counter CGMs on track to be one-hit wonders?
Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...
10 growth stocks in the S&P 500's bargain sector
The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...
Oura Ring 4 long-term review: Out ahead of its rivals
Oura’s latest Ring is the best smart ring on the market. But its range of functions remains limited by its size and the fact ...
DexCom Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Shares of DexCom Inc. DXCM rose 1.51% to $88.78 Wednesday, on what proved to be an all-around great trading session for the ...
drugdeliverybusiness14h
Dexcom establishes direct presence in Italy with CGM launch, ends distro deal with Roche
Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...
On-Body Drug Delivery Devices Market Hits US$ 390.7 Million in 2023, Set to Reach US$ 796.1 Million by 2034 with a 6.8% CAGR | TMR Research
The On-Body Drug Delivery Devices market is witnessing significant growth, driven by the increasing demand for ...